SEC Form 4Coverage since Jul 8, 2026
$AKTS insider trading
Over the last 12 months, Aktis Oncology insiders reported no purchases and 4 sales totaling $3.0M across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.0M 4 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $AKTS · 12Mvia TradingView
Top insiders · 12m
Herrmann Ken—2× · $197K
Ron-Bigger ShulamitChief Operating Officer1× · $1.4M
Czibere AkosChief Medical Officer1× · $1.4M
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Herrmann KenD | ▼ Sale | 4,856 | $24.56 | $119K | -100% | 2 tranches |
| Jul 17, 2026 | Herrmann KenD | ▼ Sale | 3,065 | $25.21 | $77K | -100% | — |
| Jul 8, 2026 | Ron-Bigger ShulamitChief Operating Officer · O | ▼ Sale | 50,000 | $27.75 | $1.4M | -100% | 3 tranches |
| Jul 8, 2026 | Czibere AkosChief Medical Officer · O | ▼ Sale | 50,000 | $27.77 | $1.4M | -100% | 3 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AKTS feed.